These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 32325112)

  • 1. An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs).
    Avila AM; Bebenek I; Bonzo JA; Bourcier T; Davis Bruno KL; Carlson DB; Dubinion J; Elayan I; Harrouk W; Lee SL; Mendrick DL; Merrill JC; Peretz J; Place E; Saulnier M; Wange RL; Yao J; Zhao D; Brown PC
    Regul Toxicol Pharmacol; 2020 Jul; 114():104662. PubMed ID: 32325112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologies.
    Avila AM; Bebenek I; Mendrick DL; Peretz J; Yao J; Brown PC
    Regul Toxicol Pharmacol; 2023 Mar; 139():105345. PubMed ID: 36746323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment.
    Turner J; Pound P; Owen C; Hutchinson I; Hop M; Chau DYS; Barrios Silva LV; Coleman M; Dubourg A; Harries LW; Hutter V; Kenna JG; Lauschke VM; Neuhaus W; Roper C; Watkins PB; Welch J; Alvarez LR; Taylor K
    ALTEX; 2023; 40(3):519-533. PubMed ID: 36692187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolites in safety testing.
    Robison TW; Jacobs A
    Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the Use of KIM-1 in Drug Development and Research Following FDA Qualification.
    Chen R; Sanyal S; Thompson A; Ix JH; Haskins K; Muldowney L; Amur S
    Clin Pharmacol Ther; 2018 Dec; 104(6):1175-1181. PubMed ID: 29761868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An industry perspective on the FDA Modernization Act 2.0/3.0: potential next steps for sponsors to reduce animal use in drug development.
    Carratt SA; Zuch de Zafra CL; Oziolor E; Rana P; Vansell NR; Mangipudy R; Vaidya VS
    Toxicol Sci; 2025 Jan; 203(1):28-34. PubMed ID: 39298459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancing food safety risk assessment in China: development of new approach methodologies (NAMs).
    Yang D; Yang H; Shi M; Jia X; Sui H; Liu Z; Wu Y
    Front Toxicol; 2023; 5():1292373. PubMed ID: 38046399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Qualification of a non-animal vaginal irritation method admitted as nonclinical assessment model (NAM) in the Incubator Phase of the United States Food and Drug Administration (US FDA) Medical Devices Development Tool (MDDT).
    Costin GE; Hill E; Brown J; Clippinger AJ
    Toxicol In Vitro; 2020 Feb; 62():104680. PubMed ID: 31626901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FutureTox IV Workshop Summary: Predictive Toxicology for Healthy Children.
    Knudsen TB; Fitzpatrick SC; De Abrew KN; Birnbaum LS; Chappelle A; Daston GP; Dolinoy DC; Elder A; Euling S; Faustman EM; Fedinick KP; Franzosa JA; Haggard DE; Haws L; Kleinstreuer NC; Buck Louis GM; Mendrick DL; Rudel R; Saili KS; Schug TT; Tanguay RL; Turley AE; Wetmore BA; White KW; Zurlinden TJ
    Toxicol Sci; 2021 Apr; 180(2):198-211. PubMed ID: 33555348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International Conference on Harmonisation; Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Jan; 75(13):3471-2. PubMed ID: 20349552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(202):61133-4. PubMed ID: 16237859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leveraging the Value of CDISC SEND Data Sets for Cross-Study Analysis: Incidence of Microscopic Findings in Control Animals.
    Carfagna MA; Anderson J; Eley C; Fukushima T; Horvath J; Houser W; Larsen B; Page T; Russo D; Sloan C; Snyder K; Thompson R; Ullmann G; Whittaker M
    Chem Res Toxicol; 2021 Feb; 34(2):483-494. PubMed ID: 33325690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of the new FDA/CDER immunotoxicology guidance for drugs.
    Hastings KL;
    Int Immunopharmacol; 2002 Oct; 2(11):1613-8. PubMed ID: 12433062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Affecting the Perception of New Approach Methodologies (NAMs) in the Ecotoxicology Community.
    Mondou M; Hickey GM; Rahman HT; Maguire S; Pain G; Crump D; Hecker M; Basu N
    Integr Environ Assess Manag; 2020 Mar; 16(2):269-281. PubMed ID: 31944596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity of excipients--a Food and Drug Administration perspective.
    Osterberg RE; See NA
    Int J Toxicol; 2003; 22(5):377-80. PubMed ID: 14555410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Integrated Review: FDA Modernizes the Review of New Drug Marketing Applications.
    Hearns-Stewart RM; Farley J; Lee KJ; Connelly S; Lowy N; Stein P; Bugin K
    Ther Innov Regul Sci; 2021 May; 55(3):467-472. PubMed ID: 33236259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonclinical safety testing of imaging agents, contrast agents and radiopharmaceuticals.
    Baldrick P
    J Appl Toxicol; 2021 Jan; 41(1):95-104. PubMed ID: 32833236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancing New Approach Methodologies (NAMs) for Tobacco Harm Reduction: Synopsis from the 2021 CORESTA SSPT-NAMs Symposium.
    Lee KM; Corley R; Jarabek AM; Kleinstreuer N; Paini A; Stucki AO; Bell S
    Toxics; 2022 Dec; 10(12):. PubMed ID: 36548593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerating the Pace of Chemical Risk Assessment.
    Kavlock RJ; Bahadori T; Barton-Maclaren TS; Gwinn MR; Rasenberg M; Thomas RS
    Chem Res Toxicol; 2018 May; 31(5):287-290. PubMed ID: 29600706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop.
    Buckley LA; Benson K; Davis-Bruno K; Dempster M; Finch GL; Harlow P; Haggerty HG; Hart T; Kinter L; Leighton JK; McNulty J; Roskos L; Saber H; Stauber A; Tabrizi M
    Int J Toxicol; 2008; 27(4):303-12. PubMed ID: 18821393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.